Potent Inhibition of Hendra Virus Infection via RNA Interference and Poly I: C Immune Activation

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  McCaskill, Jana L ^a   Marsh, Glenn A ^b   Monaghan, Paul ^b   Wang, Lin Fa ^b   Doran, Timothy ^b   McMillan, Nigel A J ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b CSIRO   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN; RIG LIKE RECEPTOR AGONIST; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3 AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HENDRA VIRUS; HENDRA VIRUS INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; M GENE; N GENE; NONHUMAN; P GENE; PROTEIN BLOOD LEVEL; RNA INTERFERENCE; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

HELA CELLS; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; HUMANS; POLY I-C; RNA INTERFERENCE; TOLL-LIKE RECEPTOR 3; VIRAL LOAD;

EID: 84877784365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064360     Document Type: Article

References (35)

1. Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, et al. (1995) Infection of humans and horses by a newly described morbillivirus. Med J Aust 162: 642-645.
2. Marsh GA, Wang LF (2012) Hendra and Nipah viruses: why are they so deadly? Curr Opin Virol.
3. Broder CC, (2012) Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol 2: 176-187.
4. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, et al. (2011) A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med 3: 105ra103.
5. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, et al. (2003) Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. Journal of Virology 77: 1501-1511.
6. Rodriguez JJ, Horvath CM, (2004) Host evasion by emerging paramyxoviruses: Hendra virus and Nipah virus v proteins inhibit interferon signaling. Viral Immunol 17: 210-219.
7. O'Sullivan JD, Allworth AM, Paterson DL, Snow TM, Boots R, et al. (1997) Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 349: 93-95.
8. Playford EG, McCall B, Smith G, Slinko V, Allen G, et al. (2010) Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerging Infectious Diseases 16: 219-223.
9. Bellini WJ, Harcourt BH, Bowden N, Rota PA, (2005) Nipah virus: an emergent paramyxovirus causing severe encephalitis in humans. J Neurovirol 11: 481-487.
10. Homaira N, Rahman M, Hossain MJ, Epstein JH, Sultana R, et al. (2010) Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiology and Infection: 1-7.
11. Luby SP, Rahman M, Hossain MJ, Blum LS, Husain MM, et al. (2006) Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis 12: 1888-1894.
12. Burnett JC, Rossi JJ, Tiemann K, (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnology Journal 6: 1130-1146.
13. Gish RG, Satishchandran C, Young M, Pachuk C, (2011) RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. Antiviral Therapy 16: 547-554.
14. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, et al. (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America 107: 8800-8805.
15. Mungall BA, Schopman NC, Lambeth LS, Doran TJ, (2008) Inhibition of Henipavirus infection by RNA interference. Antiviral Res 80: 324-331.
16. Wright PJ, Crameri G, Eaton BT, (2005) RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription. Archives of Virology 150: 521-532.
17. Marsh GA, Virtue ER, Smith I, Todd S, Arkinstall R, et al. (2013) Recombinant Hendra viruses expressing a reporter gene retain pathogenicity in ferrets. Virology Journal 10: 95.
18. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, et al. (2011) siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol.
19. Wu SY, Singhania A, Burgess M, Putral LN, Kirkpatrick C, et al. (2011) Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Ther 18: 14-22.
20. Virtue ER, Marsh GA, Wang LF, (2011) Interferon signaling remains functional during henipavirus infection of human cell lines. J Virol 85: 4031-4034.
21. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, et al. (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. Journal of Experimental Medicine 205: 1601-1610.
22. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, et al. (2006) Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proceedings of the National Academy of Sciences of the United States of America 103: 8459-8464.
23. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, et al. (2007) Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerging Infectious Diseases 13: 1031-1037.
24. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B, (2003) Human immunodeficiency virus type 1 escape from RNA interference. Journal of Virology 77: 11531-11535.
25. Marsh GA, Todd S, Foord A, Hansson E, Davies K, et al. (2010) Genome sequence conservation of Hendra virus isolates during spillover to horses, Australia. Emerging Infectious Diseases 16: 1767-1769.
26. Matsumoto M, Seya T, (2008) TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60: 805-812.
27. Buti M, Esteban R, (2011) 1990-2010: two decades of interferon-based therapy. Clinics in Liver Disease 15: 473-482.
28. Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, et al. (2006) Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrobial Agents and Chemotherapy 50: 1768-1772.
29. Rodriguez JJ, Wang LF, Horvath CM, (2003) Hendra virus V protein inhibits interferon signaling by preventing STAT1 and STAT2 nuclear accumulation. J Virol 77: 11842-11845.
30. Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF, (2005) Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. Journal of Virology 79: 6078-6088.
31. Shaw ML, Garcia-Sastre A, Palese P, Basler CF, (2004) Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. Journal of Virology 78: 5633-5641.
32. Marsh GA, Haining J, Hancock TJ, Robinson R, Foord AJ, et al. (2011) Experimental infection of horses with Hendra virus/Australia/horse/2008/Redlands. Emerg Infect Dis 17: 2232-2238.
33. Crameri G, Wang LF, Morrissy C, White J, Eaton BT, (2002) A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies. J Virol Methods 99: 41-51.
34. Reed LJ, Muench H, (1938) A simple method of estimating fifty per cent endpoints. American Journal of Epidemiology 27: 493-497.
35. Tulac S, Dosiou C, Suchanek E, Giudice LC, (2004) Silencing lamin A/C in human endometrial stromal cells: a model to investigate endometrial gene function and regulation. Mol Hum Reprod 10: 705-711.